Galmed's New Oral Drug Formulation Boosts Bioavailability by ~500%
GLMD sits 54% above its 52-week low of $0.411.
Summary
Galmed Pharmaceuticals announced highly positive results from its first-in-man pharmacokinetics study of an oral formulation of Aramchol Meglumine (AM). The study demonstrated that the 400mg AM formulation increased bioavailability by approximately 500% compared to the previous Aramchol Free Acid (AA) 300mg formulation. This substantial improvement in bioavailability is a critical positive development for the drug candidate, indicating a potentially more effective and efficient drug profile. For a micro-cap biotech company, such strong early-stage clinical data significantly de-risks the development pathway and is highly material to the investment thesis. This news is distinct from the recent collaboration announcement with Tissue Dynamics. Investors will now closely monitor the progression of Aramchol Meglumine into subsequent clinical trial phases.
At the time of this announcement, GLMD was trading at $0.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9M. The 52-week trading range was $0.41 to $2.34. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.